710 related articles for article (PubMed ID: 31300379)
1. Diagnosis and treatment of Pneumocystis jirovecii pneumonia in HIV-infected or non-HIV-infected patients-difficulties in diagnosis and adverse effects of trimethoprim-sulfamethoxazole.
Kato H; Samukawa S; Takahashi H; Nakajima H
J Infect Chemother; 2019 Nov; 25(11):920-924. PubMed ID: 31300379
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Diagnostic, and Treatment Disparities between HIV-Infected and Non-HIV-Infected Immunocompromised Patients with Pneumocystis jirovecii Pneumonia.
Salzer HJF; Schäfer G; Hoenigl M; Günther G; Hoffmann C; Kalsdorf B; Alanio A; Lange C
Respiration; 2018; 96(1):52-65. PubMed ID: 29635251
[TBL] [Abstract][Full Text] [Related]
3. Acute psychosis related to use of trimethoprim/sulfamethoxazole in the treatment of HIV-infected patients with Pneumocystis jirovecii pneumonia: a multicentre, retrospective study.
Lee KY; Huang CH; Tang HJ; Yang CJ; Ko WC; Chen YH; Lee YC; Hung CC
J Antimicrob Chemother; 2012 Nov; 67(11):2749-54. PubMed ID: 22821870
[TBL] [Abstract][Full Text] [Related]
4. How to diagnose and treat a patient without human immunodeficiency virus infection having Pneumocystis jirovecii pneumonia?
Hänsel L; Schumacher J; Denis B; Hamane S; Cornely OA; Koehler P
Clin Microbiol Infect; 2023 Aug; 29(8):1015-1023. PubMed ID: 37086781
[TBL] [Abstract][Full Text] [Related]
5. Acute exacerbation of interstitial pneumonia associated with rheumatoid arthritis during the course of treatment for Pneumocystis jirovecii pneumonia: a case report.
Kuroda T; Takeuchi H; Nozawa Y; Sato H; Nakatsue T; Wada Y; Moriyama H; Nakano M; Narita I
BMC Res Notes; 2016 Apr; 9():240. PubMed ID: 27113212
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review.
Huang YS; Yang JJ; Lee NY; Chen GJ; Ko WC; Sun HY; Hung CC
Expert Rev Anti Infect Ther; 2017 Sep; 15(9):873-892. PubMed ID: 28782390
[TBL] [Abstract][Full Text] [Related]
7. Deterioration of the immune response induced by sulfamethoxazole-trimethoprim in a rheumatoid arthritis patient with Pneumocystis jirovecii pneumonia.
Gochi M; Takayanagi N; Ishiguro T; Miyahara Y; Yanagisawa T; Shimizu Y; Sugita Y
Intern Med; 2014; 53(11):1137-41. PubMed ID: 24881737
[TBL] [Abstract][Full Text] [Related]
8. Anidulafungin as an alternative treatment for Pneumocystis jirovecii pneumonia in patients who cannot tolerate trimethoprim/sulfamethoxazole.
Chen PY; Yu CJ; Chien JY; Hsueh PR
Int J Antimicrob Agents; 2020 Jan; 55(1):105820. PubMed ID: 31622654
[TBL] [Abstract][Full Text] [Related]
9. A Four-Center Retrospective Study of the Efficacy and Toxicity of Low-Dose Trimethoprim-Sulfamethoxazole for the Treatment of Pneumocystis Pneumonia in Patients without HIV Infection.
Kosaka M; Ushiki A; Ikuyama Y; Hirai K; Matsuo A; Hachiya T; Hanaoka M
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893787
[TBL] [Abstract][Full Text] [Related]
10. High Prevalence of Pneumocystis jirovecii Dihydropteroate Synthase Gene Mutations in Patients with a First Episode of Pneumocystis Pneumonia in Santiago, Chile, and Clinical Response to Trimethoprim-Sulfamethoxazole Therapy.
Ponce CA; Chabé M; George C; Cárdenas A; Durán L; Guerrero J; Bustamante R; Matos O; Huang L; Miller RF; Vargas SL
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855071
[TBL] [Abstract][Full Text] [Related]
11. Predisposing factors, clinical characteristics and outcome of Pneumonocystis jirovecii pneumonia in HIV-negative patients.
Kofteridis DP; Valachis A; Velegraki M; Antoniou M; Christofaki M; Vrentzos GE; Andrianaki AM; Samonis G
J Infect Chemother; 2014 Jul; 20(7):412-6. PubMed ID: 24767467
[TBL] [Abstract][Full Text] [Related]
12. Good outcome with trimethoprim 10 mg/kg/day-sulfamethoxazole 50 mg/kg/day for Pneumocystis jirovecii pneumonia in HIV infected patients.
Thomas M; Rupali P; Woodhouse A; Ellis-Pegler R
Scand J Infect Dis; 2009; 41(11-12):862-8. PubMed ID: 19922070
[TBL] [Abstract][Full Text] [Related]
13. Dihydropteroate synthase (DHPS) gene mutation study in HIV-Infected Indian patients with Pneumocystis jirovecii pneumonia.
Tyagi AK; Mirdha BR; Luthra K; Guleria R; Mohan A; Singh UB; Samantaray JC; Dar L; Iyer VK; Chaudhry R
J Infect Dev Ctries; 2010 Nov; 4(11):761-6. PubMed ID: 21252456
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients.
Moon SM; Kim T; Sung H; Kim MN; Kim SH; Choi SH; Jeong JY; Woo JH; Kim YS; Lee SO
Antimicrob Agents Chemother; 2011 Oct; 55(10):4613-8. PubMed ID: 21788460
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study.
Helweg-Larsen J; Benfield T; Atzori C; Miller RF
J Antimicrob Chemother; 2009 Dec; 64(6):1282-90. PubMed ID: 19858161
[TBL] [Abstract][Full Text] [Related]
16. Serial change in serum biomarkers during treatment of Non-HIV Pneumocystis pneumonia.
Urabe N; Sakamoto S; Sano G; Ito A; Sekiguchi R; Homma S
J Infect Chemother; 2019 Dec; 25(12):936-942. PubMed ID: 31186197
[TBL] [Abstract][Full Text] [Related]
17. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-β-D-glucan in HIV-infected patients: a retrospective case control study.
Hammarström H; Grankvist A; Broman I; Kondori N; Wennerås C; Gisslen M; Friman V
BMC Infect Dis; 2019 Jul; 19(1):658. PubMed ID: 31337356
[TBL] [Abstract][Full Text] [Related]
18. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia.
Rabodonirina M; Vaillant L; Taffé P; Nahimana A; Gillibert RP; Vanhems P; Hauser PM
Emerg Infect Dis; 2013 Jan; 19(1):21-8; quiz 186. PubMed ID: 23260763
[TBL] [Abstract][Full Text] [Related]
19. Pneumocystis jirovecii pneumonia in patients with and without human immunodeficiency virus infection.
Su YS; Lu JJ; Perng CL; Chang FY
J Microbiol Immunol Infect; 2008 Dec; 41(6):478-82. PubMed ID: 19255691
[TBL] [Abstract][Full Text] [Related]
20. Low prevalence of DHFR and DHPS mutations in Pneumocystis jirovecii strains obtained from a German cohort.
Suárez I; Roderus L; van Gumpel E; Jung N; Lehmann C; Fätkenheuer G; Hartmann P; Plum G; Rybniker J
Infection; 2017 Jun; 45(3):341-347. PubMed ID: 28303545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
